Vinpocetine, tablets 5 mg 50 pcs

Improves brain metabolism by increasing glucose and oxygen uptake by brain tissue. Increases resistance of neurons to hypoxia; facilitates transport of oxygen and energy supply substrates to tissues (due to decreased affinity of red blood cells to it, increased glucose uptake and metabolism, switching it to a more energetically beneficial aerobic direction).

It selectively blocks Ca2+/dependent phosphodiesterase (PDE); increases brain levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP). Increases ATP concentration and ATP/AMP ratio in brain tissues; enhances brain noradrenaline and serotonin metabolism; stimulates ascending branch of noradrenergic system, has antioxidant effect.

Indications

• Neurology: symptomatic therapy of ischemic stroke, vascular vertebrobasilar insufficiency, vascular dementia, atherosclerosis of cerebral vessels, post-traumatic, hypertensive encephalopathy.
• Ophthalmology: chronic vascular diseases of the retina and choroid.
• Otology: perceptual hearing loss, Meniere’s disease, tinnitus.

.

Active ingredient

Vinpocetine

Composition

1 tablet contains:
active ingredient:
vinpocetine – 0.005 g
excipients:
lactose (milk sugar) – 0,17500 g
colloidal silica (aerosil) – 0,00125 g
potato starch – 0,06625 g
talc – 0,00125 g
magnesium stearate – 0,00125 g

How to take, the dosage

Orally, after meals, the initial dose is 15 mg/day, the standard daily dose is 5-10 mg three times a day. The maximum daily dose is 30 mg. The course of treatment is 1-3 months.

Interaction

Increased hypotensive effect is possible with concomitant use with methyldopa (requires blood pressure control).
Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when using simultaneously with drugs of central action, antiarrhythmic drugs and anticoagulants.

Special Instructions

In case of initial Q-T interval prolongation, as well as in case of concomitant use with drugs prolonging Q-T interval, periodic ECG control is necessary during vinpocetine treatment.

Contraindications

Acute phase of hemorrhagic stroke, severe coronary heart disease, severe heart rhythm disturbances. Hypersensitivity to vinpocetine or other components of the drug. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption, because the drug contains lactose.
Pregnancy, lactation.
Under 18 years of age (due to the lack of data from clinical trials).

With caution
Coronary heart disease (severe course), severe arrhythmia (parenteral administration). In hemorrhagic stroke parenteral administration is possible only after the acute phenomena have subsided (usually after 5-7 days).

Side effects

Data on adverse effects are presented by systemic organ class according to the MedDRA classification and with the following frequency: infrequent (≥1/1000, < 1/100); rare (≥1/10000, < 1/1000); very rare (< 1/10000).

Overdose

Treatment: gastric lavage, intake of activated charcoal, symptomatic treatment.

Similarities

Vinpocetine, Cavinton, Cavinton Forte, Cavinton Comfort